JPMorgan Chase & Co. Has $4.59 Million Stock Position in Ingevity Co. (NYSE:NGVT)

JPMorgan Chase & Co. increased its position in Ingevity Co. (NYSE:NGVT - Free Report) by 24.9% in the 3rd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 117,581 shares of the company's stock after purchasing an additional 23,460 shares during the quarter. JPMorgan Chase & Co. owned approximately 0.32% of Ingevity worth $4,586,000 at the end of the most recent quarter.

Other institutional investors have also recently bought and sold shares of the company. State Street Corp raised its holdings in shares of Ingevity by 14.7% in the 3rd quarter. State Street Corp now owns 1,546,957 shares of the company's stock worth $60,331,000 after buying an additional 198,300 shares in the last quarter. Thrivent Financial for Lutherans raised its stake in Ingevity by 1.7% during the third quarter. Thrivent Financial for Lutherans now owns 1,383,053 shares of the company's stock worth $53,939,000 after acquiring an additional 23,497 shares in the last quarter. Segall Bryant & Hamill LLC lifted its holdings in shares of Ingevity by 33.5% during the third quarter. Segall Bryant & Hamill LLC now owns 1,185,415 shares of the company's stock valued at $46,231,000 after acquiring an additional 297,135 shares during the period. Royce & Associates LP boosted its stake in shares of Ingevity by 23.3% in the 3rd quarter. Royce & Associates LP now owns 933,677 shares of the company's stock valued at $36,413,000 after purchasing an additional 176,447 shares in the last quarter. Finally, Dimensional Fund Advisors LP grew its holdings in shares of Ingevity by 11.6% in the 2nd quarter. Dimensional Fund Advisors LP now owns 845,912 shares of the company's stock worth $36,977,000 after purchasing an additional 88,026 shares during the last quarter. Institutional investors and hedge funds own 91.59% of the company's stock.

Analyst Upgrades and Downgrades

Separately, BMO Capital Markets increased their target price on shares of Ingevity from $40.00 to $47.00 and gave the stock a "market perform" rating in a research report on Thursday, October 31st. Three equities research analysts have rated the stock with a hold rating and three have issued a buy rating to the company's stock. Based on data from MarketBeat, the company presently has an average rating of "Moderate Buy" and a consensus price target of $52.17.

Ingevity Price Performance

Ingevity stock opened at $47.07 on Friday. The business's fifty day moving average is $44.09 and its two-hundred day moving average is $40.77. The company has a debt-to-equity ratio of 6.52, a quick ratio of 1.04 and a current ratio of 1.76. The firm has a market cap of $1.71 billion, a P/E ratio of -3.03 and a beta of 1.65. Ingevity Co. has a 52 week low of $30.90 and a 52 week high of $56.29.

Ingevity (NYSE:NGVT - Get Free Report) last issued its quarterly earnings results on Tuesday, October 29th. The company reported $1.10 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.60 by $0.50. The business had revenue of $376.90 million for the quarter, compared to the consensus estimate of $376.95 million. Ingevity had a negative net margin of 38.11% and a positive return on equity of 24.46%. The firm's quarterly revenue was down 15.5% on a year-over-year basis. During the same quarter in the prior year, the company earned $1.21 EPS. Equities research analysts forecast that Ingevity Co. will post 2.55 earnings per share for the current fiscal year.

Ingevity Profile

Ingevity Corporation manufactures and sells activated carbon products, derivative specialty chemicals, and engineered polymers in North America, the Asia Pacific, Europe, the Middle East, Africa, and South America. It operates through three segments: Performance Materials, Performance Chemicals, and Advanced Polymer Technologies.